Here are relevant reports on : single-molecule-imaging-market
-
3D Imaging Market by Hardware (3D Cameras, 3D Sensors, 3D Scanners), Software (Modeling, Scanning, Layout & Animation, Visualization & Rendering, Image Reconstruction), Technology (Stereoscopic Imaging, Laser-based Imaging) - Global Forecast to 2028
The global market for 3D Imaging market is projected to reach USD 88.4 billion by 2028, at a CAGR of 20.8% during the forecast period. Major vendors in the global 3D Imaging market are GE Healthcare (US), Autodesk (US), STMicroelectronics (Switzerland), Panasonic (Japan), Sony Corporation (Japan), Trimble (US), FARO Technologies (US), Philips (Netherlands), Google (US), Adobe (US), HP (US), Dassault Systemes (France), Bentley Systems (US), Lockheed Martin (US), Topcon (Japan), Able Software (US), Maxon (Germany), ESRI (US), Archilogic (Switzerland), Pix4D (Switzerland), Brainkey (US), Precismo (US), Kaarta (US), LightCode Photonics (Estonia), Vzense Technology (US), Capoom (Istanbul), Atomontage (US), Hivemapper (US), Shapr3D (Hungary), Innersight (UK).
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Dental Imaging Market by Product (Extraoral Imaging (CBCT, Panoramic), Intraoral Imaging (X-ray, Intraoral Camera, IOL Scanner)), Application (Endodontics, Implantology), & End User (Dental Hospitals, Dental Diagnostic Centers) - Global Forecast to 2030
The global dental imaging market, valued at US$3.08 billion in 2024, stood at US$3.26 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2030, culminating in a forecasted valuation of US$4.69 billion by the end of the period. The prominent players in the dental imaging market include Envista Holdings Corporation (US), Planmeca Oy (Finland), ACTEON (UK), DENTSPLY SIRONA Inc. (US), Carestream Dental LLC (US), VATECH (South Korea), Owandy Radiology, Inc. (France), DÜRR DENTAL AG (Germany), Midmark Corporation (US), Genoray Co., Ltd. (South Korea), Asahi Roentgen Co., Ltd. (Japan), 3Shape (Denmark), PreXion, Inc. (US), Ningbo Runyes Medical Instrument Co. Ltd.(China), Cefla Medical Equipment (Italy), Apteryx Imaging (Canada), Yoshida Dental Mfg. Co., Ltd. (Japan), Align Technology Inc. (US), J. MORITA CORP (Japan), and FONA Srl (Italy).
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030
The global ophthalmology drugs market, valued at US$18.34 billion in 2024, stood at US$19.52 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$26.28 billion by the end of the period.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Lipid Nanoparticles Market by Product (Ionizable lipids, Phospholipids, Kits, Reagents), LNP Type (SLNs, NLCs), Molecule (siRNA, mRNA), Application, Service Type (Formulation Development, Manufacturing) - Global Forecast to 2029
The global lipid nanoparticles market, valued at US$261.8 million in 2023, stood at US$271.8 million in 2024 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2029, culminating in a forecasted valuation of US$350.5 million by the end of the period. The growth of this market can be attributed to factors such as the development of lipid nanoparticle-based pharmaceuticals and the expanding application of lipid nanoparticles in anti-cancer and mRNA-based therapies.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
High Throughput Process Development Market by Product (Consumables (Minicolumn, Mini Bioreactor), Instruments), Services, Software, Molecule Type (mAB), Technology (Affinity Chromatography), End User (Biopharmaceutical) - Global Forecast to 2021
The global high throughput process development market is expected to reach USD 415.5 Million in 2021 from USD 212.1 Million in 2016, at a CAGR of 14.4% from 2016 to 2021. Major players operating in the high throughput process development market include Danaher (US), GE Healthcare (US), Agilent Technologies (US), Merck Millipore (Germany), and Thermo Fisher Scientific (US).
- Published: April 2017
- Price: $ 4950
- TOC Available:
-
Contrast Enhanced Ultrasound Market by Product (Equipment, Nanoparticle & Molecule-targeted Microbubbles, Software], Application (Diagnostic, Therapeutic, CVDs, Liver, Kidney, Oncology), End User (Hospital, Clinics, ASCs) & Region - Global Forecast to 2028
The global contrast enhanced ultrasound market, valued at US$1.4 billion in 2022, stood at US$1.6 billion in 2023 and is projected to advance at a resilient CAGR of 6.1% from 2023 to 2028, culminating in a forecasted valuation of US$2.1 billion by the end of the period. The rising use of contrast agents, increasing partnerships and collaborations, and the introduction of novel technologies are expected to drive the market during the forecast period.
- Published: August 2023
- Price: $ 4950
- TOC Available:
-
Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029
The global age-related macular degeneration (AMD) drugs market, valued at US$9.55 billion in 2023, stood at US$10.46 billion in 2024 and is projected to advance at a resilient CAGR of 10.7% from 2024 to 2029, culminating in a forecasted valuation of US$17.37 billion by the end of the period. Factors such as the increase in the prevalence of AMD cases due to the changing lifestyle and dietary habits such as smoking, alcohol consumption, and lack of physical activity, a growing focus on research and development highlighted by steady development and approvals of AMD drugs along with improvements in reimbursement policies providing better and affordable access to therapeutic AMD drugs, supports the growth of this market.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030
The global biopharmaceutical contract manufacturing market, valued at US$20.51 billion in 2024, stood at US$22.40 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$34.15 billion by the end of the period. The growth is primarily driven by the rising demand for outsourcing services and an increasing need for biologics and biosimilars. However, challenges related to intellectual property rights are anticipated to pose barriers to market growth.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging & Labelling, Fill-finish), Molecule (Small, Large (ADC, CGT)) - Global Forecast to 2030
The global pharmaceutical contract manufacturing market, valued at US$193.52 billion in 2024, stood at US$209.90 billion in 2025 and is projected to advance at a resilient CAGR of 8.2% from 2025 to 2030, culminating in a forecasted valuation of US$311.95 billion by the end of the period. This is mainly due to the high demand for outsourcing services for GLP-1 manufacturing, the growing ADC outsourcing for commercialized products, and the development and patent expiry of blockbuster biologics, which are paving the way for key biosimilars.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1, GPE, CGRP), Therapeutic Area (Nephrology, Gastroenterology, Genetic, CNS, Obesity, Diabetes), Formulation (Tablet, Capsule) - Global Forecast to 2030
The global oral proteins and peptides market, valued at US$8.07 billion in 2024, stood at US$9.31 billion in 2025 and is projected to advance at a resilient CAGR of 16.4% from 2025 to 2030, culminating in a forecasted valuation of US$19.93 billion by the end of the period. This growth is driven by several factors, including the rising prevalence of chronic diseases such as diabetes, gastrointestinal disorders, and kidney diseases.
- Published: February 2025
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
